Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Azura Ophthalmics

Request full access

Developing an innovative portfolio of compounds to advance treatments for Meibomian gland dysfunction , the leading cause of Dry Eye Disease

Tel Aviv-Yafo, IsraelFounded 2014Biotech & Life Sciences

About Azura Ophthalmics

Azura Ophthalmics is a clinical-stage biopharmaceutical company focused on developing a new class of treatments for ocular surface diseases. The company was founded in 2014 by Yair Alster, M.D., and two other Israeli ophthalmologists. Dr. Alster, who serves as the Chief Technology Officer, has a notable history of co-founding several successful ophthalmic companies, including some acquired by major pharmaceutical firms like Roche-Genentech and Allergan. The company's leadership team is further strengthened by CEO Marc Gleeson, who brought extensive experience from his 14-year tenure at Allergan, where he was involved in developing and commercializing treatments for ocular surface diseases.

The company's core strategy is to apply dermatological principles to ophthalmology, specifically by developing ophthalmic keratolytics to treat the root cause of Meibomian Gland Dysfunction (MGD), a leading cause of Dry Eye Disease (DED). MGD is a progressive condition where the eyelid glands become blocked by an abnormal buildup of keratin, which alters tear film and can lead to inflammation, irritation, and corneal damage. Azura's approach addresses this by creating formulations that break down these keratin blockages, a method historically used in dermatology. This business model centers on developing and gaining regulatory approval for first-in-class pharmaceutical products to address this significant unmet need in the ophthalmic market. Operations are based in Tel Aviv, Israel, with additional activities in Australia and the United States.

Azura's lead product candidate is AZR-MD-001, a topical ophthalmic ointment containing selenium sulfide (SeS2). This product is designed to be applied to the eyelid margin to directly treat MGD. Its multi-modal mechanism of action works by softening existing keratin blockages, slowing the production of new keratin to prevent recurrence, and stimulating the glands to increase the production of lipids essential for a healthy tear film. Having successfully completed Phase 2 trials that demonstrated statistically significant improvements in both the signs and symptoms of MGD, the company has advanced AZR-MD-001 into Phase 3 registration studies. Azura has raised a total of $37.2 million over three funding rounds, with its latest Series C round in October 2020 securing $20 million from investors including OrbiMed, TPG, and Brandon Capital to fund these crucial late-stage trials.

Source: Dealroom company data

At a glance

Status
Operational
Employees
11
Open positions
None listed
Dealroom signal
32.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANT✓Other financing Sep 2022 — — Brandon BioCatalyst ↗
SERIES C✓Equity / VC Oct 2020 $20M $80M TPG Biotech · Helmedix · Brandon Capital Partners · TPG —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Azura Ophthalmics website traffic

Latest recorded traffic for Azura Ophthalmics is 1.4K monthly website visits, up 40% over the last three months. Azura Ophthalmics's team declined 21.4% over the past year.

Latest monthly visits1.4K 3-month web change+40% 1-year team growth-21.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Azura Ophthalmics in the Tel Aviv-Yafo ecosystem

Live from Dealroom

The Azura Ophthalmics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Brandon BioCatalyst

Series A4 investors entered at this stage

Series B and later2 investors entered at this stage

  • TPG Biotech
  • Brandon Capital Partners
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States37.5%
🇮🇱 Israel25%
🇦🇺 Australia12.5%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Azura Ophthalmics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Azura Ophthalmics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.